Brokers Issue Forecasts for MannKind FY2025 Earnings

MannKind Co. (NASDAQ:MNKD) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of MannKind in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of $0.34 per share for the year. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Several other equities research analysts have also recently commented on MNKD. Wells Fargo & Company assumed coverage on shares of MannKind in a research note on Friday, December 20th. They set an “overweight” rating and a $9.00 price objective for the company. StockNews.com cut MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. Finally, Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $7.00 to $10.00 in a report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, MannKind presently has an average rating of “Buy” and an average target price of $9.07.

MannKind Stock Up 2.2 %

NASDAQ:MNKD opened at $6.17 on Thursday. MannKind has a twelve month low of $3.17 and a twelve month high of $7.63. The company has a market cap of $1.70 billion, a P/E ratio of 88.14 and a beta of 1.29. The business has a 50 day moving average price of $6.51 and a two-hundred day moving average price of $6.26.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.04 EPS for the quarter, meeting analysts’ consensus estimates of $0.04. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. The company had revenue of $70.08 million for the quarter, compared to analyst estimates of $77.27 million.

Insider Buying and Selling at MannKind

In related news, Director Steven B. Binder sold 67,539 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $6.76, for a total transaction of $456,563.64. Following the completion of the sale, the director now owns 1,075,026 shares in the company, valued at approximately $7,267,175.76. This represents a 5.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stuart A. Tross sold 55,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total value of $403,700.00. Following the sale, the insider now owns 967,191 shares of the company’s stock, valued at $7,099,181.94. This trade represents a 5.38 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MannKind

Several institutional investors have recently bought and sold shares of MNKD. Millennium Management LLC increased its stake in MannKind by 189.8% in the 2nd quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company’s stock worth $24,766,000 after acquiring an additional 3,107,598 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in MannKind in the 3rd quarter worth about $12,252,000. Two Sigma Advisers LP increased its position in shares of MannKind by 60.7% during the 3rd quarter. Two Sigma Advisers LP now owns 2,648,327 shares of the biopharmaceutical company’s stock valued at $16,658,000 after purchasing an additional 1,000,600 shares during the last quarter. Parkman Healthcare Partners LLC grew its position in MannKind by 37.1% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 3,304,085 shares of the biopharmaceutical company’s stock worth $20,783,000 after acquiring an additional 894,486 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in MannKind by 421.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 471,802 shares of the biopharmaceutical company’s stock worth $2,968,000 after acquiring an additional 381,298 shares during the last quarter. Institutional investors own 49.55% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.